Immunotherapy with monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) but also anti-CTLA4, recently drastically improved survival and quality of life of NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.